Fig. 1: ScRNAseq reveals enrichment of Zip1+ fibroblasts in LLC tumours following DOX treatment. | Nature Communications

Fig. 1: ScRNAseq reveals enrichment of Zip1+ fibroblasts in LLC tumours following DOX treatment.

From: ZIP1+ fibroblasts protect lung cancer against chemotherapy via connexin-43 mediated intercellular Zn2+ transfer

Fig. 1

a Schematic of experimental design for single-cell RNA sequencing (scRNAseq) of stromal fibroblasts after chemotherapy in LLC tumour transplanted into C57BL/6-EGFP mice. b Tumour growth curve of LLC tumours treated with or without doxorubicin (DOX) as described in a. n = 3 for each group. Two-way ANOVA test for tumour growth curves. c UMAP plot displaying 19,617 cells from six mice (three treated with DOX and three PBS-treated controls), indicating the numbers of cells in each of the eight subsets. d UMAP plots showing the expression of subtype-specific marker genes. e UMAP plot showing the relative cell density ratio for DOX vs. PBS treatment. f Faceted bar graph showing the percentages of cells in each subset with PBS and DOX treatment. g Heatmap of gene-set variation analysis of hallmark signalling pathway terms in the six fibroblast subsets. h UMAP plots of RNA velocity indicating cell-fate transitions. Source data are provided as a Source Data file (b, f).

Back to article page